What is the strategy of Recordati?
Recordati S.p.A. executes a specialized pharmaceutical business strategy focused on the acquisition, development, and global commercialization of innovative proprietary prescription drugs, with a primary emphasis on treatments for rare and orphan diseases alongside established specialty primary care portfolios. The company's strategic vision relies on expanding its international commercial footprint, pursuing value-accretive product licensing deals, and leveraging strong relationships with medical professionals. This targeted dual-track approach ensures steady, resilient cash flow generation while addressing critical unmet medical needs across global healthcare markets.
Related FAQs
Recordati's corporate mission focuses on reducing the severe impact of rare and devastating diseases by discovering, developing, and providing urgently needed specialty medicines in key therapeutic areas.
The Menarini Group, headquartered in Florence, is recognized as the largest Italian pharmaceutical company and a major global healthcare enterprise.
Recordati S.p.A. is an international pharmaceutical enterprise specializing in rare diseases, specialty primary care medications, and orphan drugs.
Recordati S.p.A. was founded in 1926 by Giovanni Recordati in Correggio, Italy, initially starting as a small pharmaceutical laboratory dedicated to researching and manufacturing medicinal preparations.
The global pharmaceutical market features blockbuster medications that generate tens of billions of dollars in annual sales revenue driven by high patient demand and broad therapeutic indications.
Recordati S.p.A.
Interest rates provided by the Bank of Mauston fluctuate according to specific deposit product tiers, compounding schedules, and prevailing monetary policy adjustments set by central banking authorities.
Recordati S.p.A. is an international pharmaceutical group headquartered in Milan, Italy, dedicated to the research, development, manufacturing, and commercialization of specialized healthcare products.
Recordati Industria Chimica e Farmaceutica S.p.A., an international pharmaceutical group listed on the Borsa Italiana, maintains a market capitalization fluctuating around €10.4 billion to €10.6 billion (equivalent to approximately ₹1.
Recordati S.p.A.
Recordati S.p.A. generates annual consolidated net revenues exceeding €2.2 billion to over €2.4 billion (translating to multi-billion-euro financial metrics), confirming its prominent standing as an international specialty pharmaceutical group.